Expert Q&A: What the MMRV Vaccine Equity Data Means for Pharmacists

As debate continues over the Advisory Committee on Immunization Practices' (ACIP) September 2025 vote to stop recommending the combined measles, mumps, rubella, and varicella (MMRV) vaccine for children younger than 4—a decision currently stayed by a US District Court ruling in AAP vs Kennedy as of March 16, 2026—a new JAMA Network Open study is offering some of the first population-level evidence on who actually relies on the combination shot and what could be lost if it disappears from the recommended schedule.

Pharmacy Times spoke with Eric J. Chow, MD, MS, MPH, chief of communicable disease epidemiology and immunization at Public Health–Seattle & King County and an author of the study, to discuss the findings, what they reveal about vaccine equity, and the role pharmacists can play in helping families navigate a shifting and, at times, contradictory immunization policy landscape.

Pharmacy Times: Since MMRV recipients were more likely to be VFC-eligible and vaccinated at safety-net clinics, what specific steps can pharmacists in these settings take to make sure removing MMRV as an option doesn't create new barriers to on-time vaccination?

Eric J. Chow, MD, MS, MPH: Pharmacists have played an important role in expanding access to vaccines, are trusted health care providers in the community, and have a long track record of improving immunization uptake. In this moment, individuals may turn to their local pharmacist with questions around vaccine recommendations, availability, cost, and safety. During these encounters, pharmacists can summarize and interpret the complex landscape of vaccine recommendations and distill this into the best guidance for families. They can also serve as an advocate and reliable resource by providing information to help families get connected to VFC-enrolled health care facilities in their area that stock and administer a range of combination and monovalent vaccines, including MMRV, MMR, and Varicella.

Pharmacy Times: MMRV made up about 15% of first doses every year for a decade, even though combination vaccines are known to boost completion rates by cutting down on visits and shots. Why do you think that number never grew, and what does it tell us about the families who did choose it?

Chow: There are multiple factors at play that influence decisions around which vaccines are chosen, including number of injections, number of visits, cost, side effects, and provider recommendations. Previous CDC guidance did recommend MMR + Varicella separately over combined MMRV if parents/clinicians did not have a preference due to the small increased risk of febrile seizures. What these data tell us is that there has been a smaller but consistent percentage of families that have chosen MMRV over MMR + Varicella. Limiting vaccine choice without scientifically backed justification may deepen health disparities, particularly for families that already experience systemic and structural barriers to vaccine access.

Pharmacy Times: Given that minoritized racial and ethnic groups, catch-up dose recipients, and VFC-eligible children relied more heavily on MMRV, what do you see as the biggest risk to equitable vaccine coverage now that this option has been removed for children under 4?

Chow: Currently, the ACIP vote to not recommend the MMRV vaccine to children younger than 4 years is stayed by US District Court decision as of March 16, 2026, in the case of AAP vs Kennedy. Therefore, the MMRV vaccine is currently available to that age group. The question, however, is important and relevant to the current state of changing vaccine policies, whether it involves MMRV or another vaccine. Our study underscores the fact that federal vaccine policy decisions can exacerbate inequities if factors such as disease burden, vaccine access, and community preference are not considered in the decision-making process.

While changing vaccine policies, inconsistent recommendations, and decisions made without scientific evidence can erode trust, it is reassuring that medical societies, state and local health departments, academic institutions, and coalitions have stepped in to provide consistent communication of scientifically backed vaccine recommendations. This helps support families in their health-related decisions based on the best available evidence.

Trusted messengers have an important role to play when there is conflicting vaccine information circulating. Given this environment, collaborative efforts between public health, health care and community-based organizations are essential to mitigate inequities in vaccine coverage.